Your browser does not support javascript:   Search for gard hereSearch for news-and-events here.


Genetic and Rare Diseases Information Center (GARD)

Print friendly version

Cerebellar ataxia and hypogonadotropic hypogonadism

Other Names for this Disease
  • Cerebellar ataxia - hypogonadism
  • LHRH deficiency and ataxia
  • Luteinizing hormone releasing hormone, deficiency of with ataxia
  • Luteinizing hormone-releasing hormone deficiency with ataxia
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.


Clinical Trials & Research for this Disease

  • The Centers for Mendelian Genomics program is working to discover the causes of rare genetic disorders. For more information about applying to the research study, please visit their website.

Medical Products

The medication(s) listed in the table(s) below have been approved by the Food and Drug Administration (FDA) for treatment of this condition. The FDA Office of Orphan Products Development designates "orphan products" for those that treat rare diseases affecting fewer than 200,000 Americans. The table(s) below may not be an exhaustive list of drugs or products used to treat this condition. There may be other products available that are not considered orphan products. To search for all FDA approved drugs, visit Drugs@FDA. You can find orphan products used to treat other conditions by searching the Orphan Drug Product Designation database.

Generic Name Recombinant human luteinizing hormone
Trade Name
(Manufacturer Name)
Luveris® (injection)
(EMD Serono, Inc.)
The FDA has approved this product to be used in this manner.
Luveris (lutropin alfa for injection), concomitantly administered with Gonal-f (follitropin alfa for injection), is indicated for stimulation of follicular development in infertile hypogonadotropic hypogonadal women with profound LH deficiency (LH (less than) 1.2 IU/L).
More Information about this product Drug Information Portal